Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661414 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Lpath.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT00661414: Completed Phase 1 study of Solid Tumors, sponsored by Lpath.
NCT00661414 is a Phase 1 study of Solid Tumors that has completed, run by Lpath. The registered enrollment target is 37 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00661414, a Phase 1 study of Solid Tumors, has completed, sponsored by Lpath.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.
Conditions Studied
Interventions
- BIOLOGICAL ASONEP (sonepcizumab/LT1009)
Study Locations (3)
California
- Pacific Oncology - San Diego
- Premiere Oncology - Santa Monica
Arizona
- Premiere Oncology - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00661414 record still lists
NCT00661414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ASONEP (sonepcizumab/LT1009) is the first listed.
NCT00661414 reports a single indexed study location in California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00661414 about?
NCT00661414 is a clinical study titled "Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors". The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.
What is the current status of trial NCT00661414?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2008-04. Estimated completion is 2011-12.
What conditions does trial NCT00661414 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT00661414?
The interventions under investigation include: ASONEP (sonepcizumab/LT1009) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00661414?
This trial is sponsored by Lpath, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00661414 being conducted?
This trial has 3 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00661414's enrollment target sits among peer trials
37 102nd of 125 higher than 24 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia